| dc.contributor.author | Bunting, Apphia | |
| dc.contributor.author | Silman, Daniel | |
| dc.contributor.author | Karia, Minesh | |
| dc.contributor.author | Johnson, Sophie | |
| dc.date.accessioned | 2023-12-14T16:43:34Z | |
| dc.date.available | 2023-12-14T16:43:34Z | |
| dc.date.issued | 2023-09 | |
| dc.identifier.citation | Bunting A, Silman D, Karia M, Johnson S. Clozapine and Sweet's syndrome: case report. BJPsych Open. 2023 Sep 4;9(5):e166. | en |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1304 | |
| dc.description | Freely available online | en |
| dc.description.abstract | A patient developed fever, raised inflammatory markers and a maculopapular rash following commencement of clozapine for treatment of his schizoaffective disorder. Skin biopsy confirmed Sweet's syndrome. Identification of the cause was challenging, with a number of possible considerations including infection, malignancy and various potential drug triggers.
This case highlights the difficulties in the diagnosis of Sweet's syndrome, as well as in identifying the original trigger, which can have significant consequences for management. Withdrawal of potentially causative drugs must be balanced with their benefits, and decisions must be made in the best interests of the patient. Following two courses of prednisolone and withdrawal of clozapine, the patient's rash and systemic symptoms resolved. This confirmed the diagnosis of drug-induced Sweet's syndrome, with clozapine as the offending agent. His mental state stabilised on an alternative antipsychotic. | en |
| dc.description.uri | https://doi.org/10.1192%2Fbjo.2023.513 | en |
| dc.language.iso | en | en |
| dc.subject | Antipsychotics | en |
| dc.subject | Schizophrenia | en |
| dc.title | Clozapine and Sweet's syndrome: case report | en |
| dc.type | Article | en |